`
`
`
`IPR2017-00412
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_______________
`
`
`MONOSOL RX, LLC
`Petitioner
`
`v.
`
`ICOS CORPORATION,
`Patent Owner
`
`_______________
`
`Case: IPR2017-00412
`Patent 6,943,166 B1
`_______________
`
`
`
`
`PETITIONER MONOSOL RX, LLC’S REPLY TO PATENT OWNER’S
`OPPOSITION TO REQUEST FOR REHEARING
`
`
`
`
`
`
`
`
`
`IPR2017-00412
`
`Petitioner’s Request for Rehearing (“Request”) was premised on a proper
`
`factual and legal basis. Thus, Patent Owner’s Opposition to the Request fails.
`
`Petitioner did identify where its arguments were previously raised in the
`
`Petition. See, e.g., Req. at 5, 8, 12 (citing Pet. 33-34, 44, and 22-24); Ex. 1010.1
`
`The Opposition mistakenly argues that the Williams Declaration2 was
`
`addressed by the Board. This is wrong. The only cite to this declaration (see Opp.
`
`1, citing Dec., p. 4, 8) refers to Petitioner’s arguments – not the Board’s Analysis:
`
`• Decision at p. 4: “In support of its patentability challenges, Petitioner
`relies on the Declaration of Dr. Roger Williams (Ex. 1010).”
`• Decision at p. 8. “Pet. 15, 22, 27, 38”
`
`The first cite is a background statement, before the Board’s Analysis begins.
`
`The second cite does not list or cite the Williams Declaration. Indeed, there is no
`
`reference to the Declaration anywhere on p. 8 of the Board’s Decision.3
`
`Patent Owner inaccurately contends that Petitioner’s obvious to try position
`
`was addressed. But Petitioner submitted that the Board overlooked its obvious to
`
`try position under currently applicable law. Req. at 10-11. The case cited by the
`
`Board and by Patent Owner, In re O’Farrell, referred to the “obvious to try”
`
`standard in 1988, when it was still “improper grounds for a § 103 rejection.” 853
`
`
`1 The Cutler reference was cited in Ex. 1010 and in p. 11 of the Petition.
`2 Patent Owner argues “improper incorporation” by reference (Opp. 3), but cites no
`legal authority – just its own Preliminary Response (“Paper 9”).
`3 The Velander and Daicel cases are inapposite because the Williams Declaration
`was not conclusory and may be evaluated with other factual evidence at trial.
`
`1
`
`
`
`
`
`
`
`IPR2017-00412
`
`F.2d 894, 902 (Fed. Cir. 1988). Under post-KSR law, “obvious to try” is no longer
`
`“improper” when there is a “finite number of identified, predictable solutions.”
`
`KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398, 421 (2007). Such is the case here.
`
`Ex. 1010, ¶¶ 158-167; Pet. at 22 (finite dose range to optimize). Moreover, the
`
`Petition did address “reasonable expectation of success.” (e.g., Pet. at 12), contrary
`
`to Patent Owner’s assertions (Opp. at 2).
`
` Patent Owner suggests that Petitioner’s reliance in common sense was
`
`insufficient. Opp. at 3. But Petitioner relied on the prior art, a POSA’s ability to
`
`optimize based on the prior art, market pressure, design need, and common sense.
`
`Patent Owner argues that Dr. Williams is distinct from a POSA. Opp. at 3
`
`¶6. But Dr. Williams is a POSA, and ¶175 of Declaration shows what he believed
`
`to be public FDA correspondence. Finally, the Patent Owner mistakenly argues
`
`that the “admitted prior art” is a ground “never raised.” This is not true. Dr.
`
`Williams specifically discussed the admitted prior art as acknowledged in ’166
`
`patent. Ex. 1010, ¶¶45-51 (known problems of sildenafil including side effects)
`
`(referring to Ex. 1001, col. 2, lines 58- 65), and Daugan, which is in cited in
`
`Grounds 1-3 (Pet. 6-7), is referred to as “admitted prior art” in Ex. 1010, ¶ 131.
`
`CONCLUSION
`
`Petitioner respectfully requests rehearing and reconsideration of the decision
`
`not to institute the IPR and institution of the IPR as requested.
`
`2
`
`
`
`
`
`
`
`IPR2017-00412
`
`
`
`
`
`
`Date: August 16, 2017
`
`Customer Number: 27890
`Steptoe & Johnson LLP
`1330 Connecticut Avenue, N.W.
`Washington, DC 20036-1795
`Telephone: (202) 429-3000
`Facsimile: (202) 429-3902
`
`Respectfully Submitted,
`
`
`
`
`
`By: /Harold H. Fox/
`
`Harold H. Fox
`Reg. No. 41,498
`
`
`3
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`The undersigned hereby certifies that a copy of the foregoing PETITIONER
`
`MONOSOL RX, LLC’S REPLY TO PATENT OWNER’S OPPOSITION TO
`REQUEST FOR REHEARING was served on August 16, 2017 by filing this
`document through the Patent Trial and Appeal Board End to End system as well as
`by delivering a copy via electronic email to the attorneys of record for the Patent
`Owner’s as follows:
`Mark J. Feldstein
`mark.feldstein@finnegan.com
`
`Joshua L. Goldberg
`joshua.goldberg@finnegan.com
`
`Yieyie Yang
`yieyie.yang@finnegan.com
`
`Maureen D. Queler
`maureen.queler@finnegan.com
`
`Mark J. Stewart
`stewart_mark@lilly.com
`
`Dan L. Wood
`wood_dan_l@lilly.com
`
`Gerald P. Keleher
`keleher_gerald@lilly.com
`
`
`
`
`
`
`
`
`
`Date: August 16, 2017
`
`
`
`
`
`
`
`
`By: /Harold H. Fox/
`
`Harold H. Fox
`
`Reg. No. 41,498
`
`Counsel for MonoSol Rx, LLC
`
`